Treatment outcomes of fruquintinib combined with PD-1 inhibitors in advanced colorectal cancer: a reconstructed patient-level meta-analysis of retrospective real-world studies.
Combining two cancer drugs produces modest benefits in advanced colorectal cancer, though direct comparisons remain needed.
Pooled outcomes of 609 advanced CRC patients receiving fruquintinib+PD-1 inhibitors shows median OS 15.7 months and ORR 12%; absence of comparator group limits conclusions about added benefit vs fruquintinib monotherapy. This record was retained from the prior triage attempt for PubMed pipeline handoff.
What the study was
- Study design
- reconstructed patient-level meta-analysis of retrospective real-world studies (10 studies, n=609)
- Category
- novel_therapeutics
- Maturity
- Validated
- Journal
- BMC Cancer
Why it surfaced
Real-world meta-analysis characterizing fruquintinib+PD-1 outcomes in advanced CRC, relevant for understanding current combination immunotherapy practice patterns despite significant interpretive limitations.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.